Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00499655 · ClinicalTrials.gov registry record · Phase 2
Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
NCT00499655 is a Phase 2 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 107 participants.
The verdict
NCT00499655, a Phase 2 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
Study Summary
RATIONALE: Erlotinib hydrochloride and celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Celecoxib may also stop the growth of lung cancer by blocking blood flow to the tumor. Giving erlotinib hydrochloride together with celecoxib may kill more tumor cells. PURPOSE: This randomized phase II trial is studying how well giving erlotinib hydrochloride together with celecoxib works compared with erlotinib hydrochloride alone in treating patients with stage IIIB-IV non-small cell lung cancer.
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- OTHER immunohistochemistry staining method
- DRUG erlotinib hydrochloride
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2007-11 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00499655
The ClinicalTrials.gov registry entry for NCT00499655 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00499655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00499655 about?
NCT00499655 is a clinical study titled "Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer". RATIONALE: Erlotinib hydrochloride and celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Celecoxib may also stop the growth of lung cancer by blocking blood flow to the tumor. Giving erlotinib hydrochloride together with celecoxib may kill more tumo...
What is the current status of trial NCT00499655?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2007-11. Estimated completion is 2016-12.
What interventions are being tested in trial NCT00499655?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), immunohistochemistry staining method (OTHER), erlotinib hydrochloride (DRUG), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00499655?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.